Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report)’s share price traded down 4.2% during mid-day trading on Friday . The stock traded as low as $8.54 and last traded at $8.52. 272,611 shares ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...